Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Meningitis Vax Approved in Canada | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Novartis Meningitis Vax Approved in Canada

Bexsero cleared for patients two months through 17 years of age

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Health Canada has approved Novartis‘ Bexsero (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) for use in individuals from two months through 17 years of age. Bexsero is the first broad coverage vaccine to help protect against meningococcal serogroup B (MenB) disease, including infants, toddlers and adolescents who are at the greatest risk of infection.
 
Meningococcal disease is caused by Neisseria meningitidis. Five main groups of meningococcal bacteria (A, B, C, W and Y) cause virtually all cases around the world. Prior to Bexsero, vaccines were available to help protect only against A, C, W and Y strains.
 
Bexsero is the first broad coverage meningococcal MenB vaccine to demonstrate an immune response in infants, the population at greatest risk for developing this disease. Bexsero will be available in early 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics